Sirtex Medical Inc.

Sirtex Medical Inc., a for-profit medical device manufacturer headquartered in Woburn, Massachusetts, supplies Y-90 SIR-Spheres resin microspheres and selective internal radiation therapy (SIRT) devices to the Department of Veterans Affairs, Defense Health Agency, and Army Medical Command as a prime contractor operating under full and open competition with no small business set-aside designation.

Sirtex's federal footprint is concentrated in specialized radiopharmaceutical procurement across three customer agencies that account for 96% of combined potential value. The Defense Health Agency leads by dollar magnitude with 32 awards worth $11.3 million in combined potential value; the VA's Veterans Integrated Service Network 21 follows with 64 awards worth $10.9 million; and Army Medical Command holds 100 awards worth $10.1 million. The vendor also maintains relationships with four additional VA service networks (VISN 22, VISN 19, VISN 8, and VISN 17), each placing smaller orders. Across ten distinct customer agencies, the vendor holds $42.6 million in combined potential value across 270 awards, with $15.9 million obligated as of the source date.

Sirtex holds three parent blanket purchase agreements that anchor its federal business. An Army Medical Command BPA (W81K0012A0013) carries 61 task orders valued at $2.1 million combined potential value. A VA VISN 21 BPA (VA26115A0027) has generated 32 task orders worth $9.8 million combined potential value. A Defense Health Agency BPA (HT001416A0115) supports 11 task orders worth $1.4 million combined potential value. Most recently, VISN 22 awarded a single-award indefinite-delivery contract effective January 1, 2026, through December 31, 2026 (with option years through 2030) for $3.74 million, procuring Y-90 SIR-Spheres resin microspheres, dose preparation services, and dose draw split dose fees; two delivery orders have issued under this vehicle to date, totaling $687,996. A second single-award BPA with VISN 19 effective July 15, 2025, through July 14, 2028, carries a $708,270 ceiling and has generated five BPA calls totaling $236,715. The Defense Health Agency awarded a single-award BPA effective June 10, 2025, through June 9, 2030, with a $1.1 million ceiling.

Recent representative work illustrates Sirtex's core capability: a $723,006 BPA call from VISN 19 on August 1, 2026, for Y-90 SIR-Spheres resin microspheres; a $487,056 delivery order from VISN 22 on January 1, 2026, for microspheres; a $551,117 purchase order from the Defense Health Agency on July 8, 2024, under a total small business set-aside for Y-90 SIR-Spheres resin microspheres to treat metastatic liver tumors; and a $185,737 purchase order from Army Medical Command on October 1, 2024, for SIR-Spheres doses at William Beaumont Army Medical Center, awarded on a sole-source basis under FAR 13.106-1(b)(i) citing Sirtex's exclusive licensing agreement for the SIR-Spheres product. A time-sensitive June 2026 purchase order from the Defense Health Agency for $21,229 exemplifies the vendor's role in emergency-response cancer care: the order carried custom-dosed Y-90 microspheres required by July 1, 2026, for emergency liver-tumor intervention at Madigan Army Medical Center, sole-sourced under FAR 12.102(b) as the only source capable of meeting technical specifications and the emergent timeline.

Activity has remained flat over the past five years, averaging roughly eleven awards annually from 2022 to 2025, with eight awards recorded in 2026 to date. Nine awards (combined potential value $2.3 million) carry ultimate completion dates within the next twenty-four months, representing recompete exposure for the vendor. Sirtex competes almost exclusively under full and open competition rather than set-asides; two outlier awards carry total small business set-aside designations. The vendor's awards cluster around irradiation apparatus manufacturing (82 awards), pharmaceutical preparation manufacturing (81 awards), and surgical appliance and supplies manufacturing (72 awards) across NAICS classifications, with the vast majority categorized under PSC codes for drugs and biologicals (146 awards) and medical and surgical instruments, equipment, and supplies (99 awards). All work is performed at Sirtex's Woburn facility or subordinate customer sites at VA medical centers and military medical facilities nationwide.

Sirtex Medical Inc mission is to improve the quality and longevity of patients' lives by providing innovative interventional oncology solutions.